
usd may pm et
summari develop proprietari product use cardiologist physician heart surgeon
angioplasti heart surgeri procedur
price-to-earnings oper ep
risk assess reflect lead posit
vital market -- develop proprietari product
design enabl heart rest heal recov
improv blood flow coronari arteri howev
note highli innov competit marketplac
fiscal year end ep estim base cfra
oper earn histor earn report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
feb stock trade
star recommend
recent chang buy
hold target price
recent chang
highlight section stock report
invest rationale/risk section
stock report updat shortli
latest news stori marketscop
hold lower
target base
ep estim
multipl low-end
three-year rang lower
fy ep
initi fy ep post
mar-q ep vs equal
estim sale rose mar-q
million consensu expect
growth us impella product revenu
grew yoy believ us impella
sale weak due custom confus
relat fda letter health care provid
februari regard increas mortal
rate patient receiv impella rp
system unfortun health care
provid media outlet wrong
interpret fda letter product recal
hurt sale divert manag
attent subsequ clarifi
increas mortal rate specif
salvag patient recoveri right protocol
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview lead provid temporari mechan circulatori support
devic develop manufactur market proprietari product design enabl
heart rest heal recov improv blood flow coronari arteri end-organ and/or
temporarili perform pump function heart compani product use cardiac
catheter lab intervent cardiologist electrophysiolog lab hybrid lab heart
surgeri suit heart surgeon physician might use devic patient need
hemodynam support angioplasti heart surgeri procedur
primari product impella product portfolio includ impella impella cp impella
rp impella ld impella product pipelin includ impella impella ecp impella
btr product servic revenu near futur impella devic
work expand usag awar impella product
one recent fda-approv product impella rp heart pump indic
provid temporari right ventricular support day certain patient develop acut right
heart failur decompens follow left ventricular assist devic implant myocardi infarct
heart transplant open-heart surgeri impella rp heart pump percutan temporari
ventricular support devic fda-approv safe effect right heart failur
recent develop includ april fda approv impella cp smartassist
optic sensor februari receiv two expand pre-market approv pma fda
impella heart pump first expand approv use impella cp ld heart
pump patient cardiogen shock associ cardiomyopathi second expand pma
approv use impella impella cp heart pump elect high-risk
support appropri patient sever coronari arteri diseas complex anatomi extens
comorbid without depress eject fraction
market profil accord aha heart diseas stroke statist updat report
coronari heart diseas caus approxim one everi seven death
condit coronari arteri caus reduc blood flow insuffici oxygen deliveri
affect portion heart lead acut myocardi infarct ami commonli known heart
attack may lead heart failur condit heart unabl pump enough blood
bodi major organ
competit among provid treatment fail heart intens subject rapid
technolog chang evolv industri requir standard present futur
product could render obsolet uneconom result technolog advanc one
present futur competitor therapi includ drug therapi must
continu develop commerci new product technolog remain competit
cardiovascular medic technolog industri believ compet primarili basi
clinic superior support extens data innov featur enhanc patient benefit
product perform eas use reliabl
heart replac devic research effort canada europ japan
addit sever compani includ
sever early-stag compani develop heart assist product includ implant left
ventricular assist devic miniatur rotari ventricular assist devic directli indirectli
compet product
financi trend revenu grew million fy million fy
five-year cumul annual growth rate compound-annual-growth-rate revenu -- one highest growth rate
medic equip suppli industri five-year ep compound-annual-growth-rate even higher ep
fy vs fy fy histor debt cash
flow grow free cash flow defin cash flow oper less capit
expenditur grew million million fy million fy think
financi sound posit
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
fairli valu
neutral sinc march technic indic
neutral
figur base fiscal year-end price
growth rate averag
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook health care
equip sub-industri next month
neutral continu expect compani
sub-industri achiev robust organ
growth posit macroeconom environ
compani gener benefit lax
 food drug administr fda
mani product area histor
recession-resist equip use
non-elect procedur howev valuat
health care equip compani elev
rel
suggest posit fundament
reflect share think
higher valuat sub-industri mostli
warrant recent expand margin
robust revenu growth weaker sentiment
constant currenc basi expect
revenu sub-industri continu
rise high-single-digit low-teen
percentag driven continu pipelin
innov new product emerg market
expans speed new product
come market increas recent year
success effort fda
reduc approv time medic devic
time see price pressur
incess headwind medic equip
impact trade war appear mild
far medic equip compani
accord medic devic trade
tariff billion medic
technolog export septemb
howev us chines govern
seek lower health care cost provid
equip manufactur insul
industri
possibl threat state health
care system lawsuit texa
rule unconstitut
current expect upheld upon
appeal howev decis could take
coupl year reach democrat
control hous repres
period think
see substanti effort republican
trump administr tri repeal
anoth legisl issu could impact
medic equip manufactur
potenti return medic devic tax
medic devic tax suspend
end congress fail
repeal suspend tax medic
devic manufactur could significantli
hospit spend larg driver medic
equip sale robust
strong economi tax cut
job act tcja weaker growth
outlook economi roll-off
individu mandat think
hospit could see financi
pressur could pressur sale
gener see posit long-term
fundament includ increas global
demand qualiti health care age
popul rise outlay lead
steadi flow innov product
revenu growth year-to-d march
 health equip index
appreci vs increas
valu composit index
 health equip
sub-index rose vs declin
base index
five-year market price perform may
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
higher estim rais fy ep
initi fy ep mar-q sale increas
million us impella heart pump product revenu rose
million increas patient util outsid us impella revenu
grew million primarili driven increas german
revenu million although provid specif number
compani highlight exceed fy revenu goal japan
also expect add million japan revenu fy encourag
compani explor new use technolog next year
howev time wari lofti valuat /kevin huang
rais target price well peer
ratio base fy march ep estim
rais fy ep estim dec-q ep vs
ahead estim sale rose sale
intern sale primarili germani japan smaller base
anticip continu robust growth impella heart pump client base
grow intern market still earli stage see
analyst research note compani news
pm et cfra lift opinion share inc buy hold
lower target base
ep estim multipl low-end
three-year rang lower fy ep
initi fy ep post mar-q ep
vs equal estim sale rose mar-q
million consensu expect growth us impella product
revenu grew yoy believ us impella sale weak due
custom confus relat fda letter health care provid
februari regard increas mortal rate patient receiv
impella rp system unfortun health care provid media outlet
wrong interpret fda letter product recal hurt sale
divert manag attent subsequ clarifi increas
mortal rate specif salvag patient recoveri right
et cfra reiter hold opinion share inc
maintain target price above-p
ep estim multipl near averag
three-year rang keep ep
maintain ep post dec-q ep
vs miss estim sale rose near expect
driven growth impella heart pump revenu robust
increas relat intern impella sale gross margin
contract basi point due less favor sale mix
manufactur capac expans danver aachen germani japan
continu grow incred pace believ key growth driver
wide accept product nation like lead rapid
adopt surround region given among fastest grow
medic devic compani expect multipl remain elev level
forese futur kevin huang cfa angelo zino cfa
et cfra reiter hold opinion share inc
maintain target price
above-p ep estim multipl
near averag three-year rang sep-q ep
vs higher estim rais
ep maintain ep sep-q sale
increas million compris growth impella heart
pump revenu million growth outsid impella revenu
million achiev oper margin quarter
increas primarili due higher sale volum
nation cardiogen shock initi ncsi present data show
improv cardiogen shock surviv rate patient follow ncsi
protocol includ impella use survivor
discharg home nativ heart compar year surviv
rate /kevin huang cfa
lift target price
above-p ep estim multipl
near middl abmd five-year rang jun-q ep
vs lower estim rais
ep ep jun-q sale
increas million compris growth impella heart
pump revenu million growth outsid impella revenu
million continu anticip industry-lead revenu growth
especi abroad howev think stock alreadi
rais target above-p
fy ep estim multipl close
averag three-year rang mar-q ep vs
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share
grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
